Anthropic Names Six Drug-Development Partners for Claude and Says It Bought Mithril Medicine, a One-Person Biotech
Anthropic said on October 27 that it is working with six drug-development partners, including Bristol Myers Squibb, and that it acquired Mithril Medicine, a one-person company whose founder used Claude to coordinate 11 outside labs on treatments for two rare forms of muscular dystrophy. Anthropic calls the work early and mostly preclinical. R&D World reports that the mouse data come from a small, non-randomized study that has not been peer reviewed.
Anthropic's drug-development update is a claim about how a biotech can be run, not a result in patients. Its headline example is a company with one full-time employee that used Claude to coordinate outside labs, which Anthropic has now bought. Anthropic calls the work "still at an early stage" and mostly preclinical, and the earliest human trial it projects is in late 2028.
The six partners#
Anthropic said on October 27 that it is working with six partners in drug development: BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines and The Column Group.
Anthropic says that in a review exercise at Enveda, Claude caught all 11 issues that human reviewers had flagged, plus seven they had missed, and cut review time by 89%. It says Bristol Myers Squibb is using Claude in clinical trial planning and plans to expand that work in 2027.
The post also points researchers to Claude Science, the research workbench Anthropic introduced in June, and to the Life Sciences Verification Program, which sets the terms of access for vetted biology teams.
Mithril Medicine, the one-person biotech#
Anthropic says it acquired Mithril Medicine, "a one-person company" developing treatments for two rare forms of muscular dystrophy. It says founder Cody Tranbarger used Claude to coordinate 11 external labs and took the work from idea to "promising results in mice in less than 18 months."
R&D World reports that Anthropic disclosed the acquisition on October 27 but closed it in July. It reports that Mithril, based in Cambridge, Massachusetts, had one full-time employee, eight paid consultants and advisers, and 11 outside labs. Its two programs became Anthropic's first internal drug-development programs, according to R&D World, and Anthropic calls the operating model "Pipeline-in-a-Person."
How strong the evidence is so far#
R&D World reports that Anthropic's technical report on Mithril has not been peer reviewed. It says the mouse study compared seven treated animals with four controls, was not randomized, and that the report itself calls for blinded replication.
The same report examined six errors Claude made, according to R&D World. At least three reached outside labs in emails that people had edited and sent, and two went unnoticed for more than four days.
Anthropic says it expects human trials "as soon as late 2028." R&D World reports that formal drug candidates are targeted for 2027, that trials for the LAMA2 program could begin as early as late 2028, and that the second program could follow as early as 2029.
Limits#
- The partner results, including the Enveda review figures, are Anthropic's account. We did not hear from the partners.
- We did not read Anthropic's technical report. The study size, error review and timeline details come from R&D World's reporting on it.
- The trial dates are projections. No Mithril treatment has been tested in people.
- This article stays at news level and leaves out the scientific methods and treatment design described in the sources.
Sources#
- Anthropic: Early progress in drug development (October 27, 2026)
- R&D World: Anthropic acquires Mithril Medicine, a one-person biotech (October 27, 2026)
- Times of AI: Claude Science: Vertical Workbench Bet (June 30, 2026)
- Times of AI: Anthropic Splits Biology Access Into Yearly Grants and Named High-Risk Projects (September 17, 2026)